Citryll has planned the start of first in human studies for its development candidate CIT-013 for July 2021. CR2O is proud to be a part of Citryll’s exiting journey offering their services and operational expertise in early clinical development.
Citryll is a private pharmaceutical company based in Oss, the Netherlands that is dedicated to the development and commercialization of therapeutics that target NETosis and NETs. Citryll was founded by Helmuth van Es, CEO Citryll, ModiQuest B.V., originator of the tACPA patents, and Renato Chirivi, CSO Citryll and co-inventor of tACPA.
Citryll, is taking a new approach to treat autoimmune and chronic inflammatory diseases including lupus, vasculitis, rheumatoid arthritis and respiratory diseases, by targeting and inhibiting the source of auto-antigens and/or neutrophil extracellular trap (NET) derived proinflammatory and toxic molecules instead of broadly targeting acquired immunity or inflammation.
Curious to learn more about CR2O’s full-service global CRO activities, or experience with early-stage clinical trials?
Please, contact Ellemieke von Mauw:
Ellemieke von Mauw
Director Clinical Programs | Business Development
CR2O B.V.
T +31 (0)85 071 74 65 | M +31 (0)6 57 76 61 45 E | Ellemieke.vonmauw@cr2o.nl